San Francisco, CA (UroToday.com) — Men being treated for prostate cancer with abiraterone have a better quality of life than those treated with docetaxel. This is according to results from an analysis of quality of life data from the STAMPEDE trial, which was published yesterday in the Journal of Clinical Oncology.

X